| Protein Name |
Small ubiquitin-like modifier 1 |
| Gene |
SUMO1 |
| UniProt |
P63165 |
| Molecular Weight |
11.6 kDa |
| Length |
101 amino acids |
| Subcellular Localization |
Nucleus, Cytoplasm |
| Protein Family |
SUMO family, Ubiquitin-like proteins |
Sumo1 Protein Small Ubiquitin Like Modifier 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SUMO1 (Small Ubiquitin-like Modifier 1) is a member of the SUMO family of ubiquitin-like proteins, encoded by the SUMO1 gene. It plays crucial roles in post-translational modification through SUMOylation, regulating protein function, localization, stability, and interactions.1
SUMO1 is a small protein (~101 amino acids) with a ubiquitin-like fold:
- N-terminal flexible region
- Ubiquitin-like core domain
- C-terminal glycine residue for conjugation
The C-terminal region contains the motif required for conjugation:
- Gly-Gly motif essential for isopeptide bond formation
- Activation: SUMO is activated by E1 (SAE1/UBA2)
- Conjugation: Transferred to E2 (UBC9)
- Ligation: E3 ligases facilitate substrate modification
SUMO1 modifies thousands of proteins involved in:
- Transcription regulation
- DNA repair
- Signal transduction
- Nuclear transport
- Protein degradation
SUMOylation of disease-related proteins:
- Alpha-synuclein (PD): SUMOylation affects aggregation
- Tau (AD): SUMOylation influences phosphorylation
- Huntingtin (HD): SUMOylation modulates toxicity
- TDP-43 (ALS): SUMOylation affects localization
- Cancer: Altered SUMOylation of oncogenes
- Diabetes: SUMOylation of insulin signaling proteins
- SUMO: a history of modification. Molecular Cell, 2005.
- SUMOylation in neurodegenerative disease. Trends in Neurosciences, 2013.
The study of Sumo1 Protein Small Ubiquitin Like Modifier 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
SUMO1 plays a role in amyloid precursor protein (APP) processing:
- SUMOylation of BACE1 affects beta-secretase activity
- SUMOylated APP may reduce amyloid-beta production
- Competition between SUMOylation and ubiquitination influences APP trafficking
SUMO1-mediated modifications affect tau protein:
- SUMOylation at lysine residues can protect tau from degradation
- Hyper-SUMOylation associated with tau aggregation in AD brain
- SUMO-specific proteases (SENPs) are dysregulated in AD
SUMOylation modulates inflammatory responses:
- NF-κB SUMOylation negatively regulates inflammation
- SENP1 overexpression reduces neuroinflammation in models
- SUMO1 levels correlate with microglial activation markers
SUMO1 modifies alpha-synuclein (α-syn):
- SUMOylation reduces α-syn aggregation
- SUMO-deficient mutants show increased toxicity
- Parkin is a SUMO E3 ligase, linking PD genetics to SUMOylation
SUMO1 is involved in mitochondrial dynamics:
- Mitofusin 2 SUMOylation regulates mitochondrial fusion
- PINK1/Parkin mitophagy pathway involves SUMOylation
- SUMO1 protects against mitochondrial toxins
LRRK2, a major PD gene product:
- LRRK2 undergoes SUMOylation
- SUMOylation affects LRRK2 kinase activity
- G2019S mutation alters SUMOylation patterns
- Huntingtin protein is SUMOylated
- SUMOylation promotes aggregation
- SUMOylation may enhance transcriptional dysfunction
- TDP-43 SUMOylation affects aggregation
- FUS protein modifications alter nuclear import
- SOD1 SUMOylation influences mutant toxicity
SUMOylation pathway inhibitors in development:
- Ginkgolic acid (SAE inhibitor)
- 2-D08 (Ubc9 inhibitor)
- Spectomycin B1 (SENP inhibitor)
- SUMO1 overexpression strategies
- SENP modulation
- SUMO-specific protease activation
Existing drugs with SUMO modulatory effects:
- Anthrax lethal toxin (SENP1 inhibitor)
- Auranofin (thioredoxin reductase inhibitor affects SUMOylation)
- Anti-SUMO1 antibodies for immunoblotting
- SUMOylation site mapping via mass spectrometry
- SUMO-conjugating enzyme assays
- Cell cultures: HEK293, SH-SY5Y, primary neurons
- Animal models: Mouse, Drosophila, C. elegans
- iPSC-derived neurons from neurodegenerative disease patients
SUMO1 plays complex roles in neurodegeneration through post-translational modification of disease-related proteins. Both protective and pathogenic effects have been described depending on the specific substrate and cellular context. Understanding the balance between SUMOylation and ubiquitination provides insights into disease mechanisms and therapeutic targeting.
- Hay RT et al., SUMO: a history of modification. Molecular Cell, 2005.
- SUMOylation in neurodegenerative disease. Trends in Neurosciences, 2013.
Page auto-generated from NeuroWiki protein database.